Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Central/Peripheral fat mass ratio is associated with increased risk of hypertension in HIV-infected patients.

Freitas P, Carvalho D, Santos AC, Madureira AJ, Xerinda S, Martinez E, Pereira J, Sarmento A, Medina JL.

J Clin Hypertens (Greenwich). 2012 Sep;14(9):593-600. doi: 10.1111/j.1751-7176.2012.00671.x. Epub 2012 Jun 13.

2.

Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.

Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, Martinez E, Sarmento A, Medina JL.

BMC Infect Dis. 2012 Aug 6;12:180. doi: 10.1186/1471-2334-12-180.

3.

Fat mass ratio: an objective tool to define lipodystrophy in hiv-infected patients under antiretroviral therapy.

Freitas P, Santos AC, Carvalho D, Pereira J, Marques R, Martinez E, Sarmento A, Medina JL.

J Clin Densitom. 2010 Apr-Jun;13(2):197-203. doi: 10.1016/j.jocd.2010.01.005. Epub 2010 Mar 27.

PMID:
20347364
4.

Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution.

Degris E, Delpierre C, Sommet A, Sire S, Lassoued S, Aquilina C, Marchou B, Massip P, Obadia M, Marion-Latard F, Bonnet E, Bernard J.

J Clin Densitom. 2010 Apr-Jun;13(2):237-44. doi: 10.1016/j.jocd.2009.12.004. Epub 2010 Mar 27.

PMID:
20347366
5.

Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy.

Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Hervé R, Aquilina C, Labau E, Obadia M, Marchou B, Massip P, Perret B, Bernard J.

J Clin Densitom. 2005 Fall;8(3):287-92.

PMID:
16055958
6.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
7.

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.

8.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

9.

Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients.

Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, Sarmento A, Medina JL.

BMC Infect Dis. 2014 Jun 23;14:348. doi: 10.1186/1471-2334-14-348.

10.

Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome.

Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, Sarmento A, Medina JL.

BMC Infect Dis. 2014 Jun 23;14:347. doi: 10.1186/1471-2334-14-347.

11.

Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel MJ, De José Gómez MI.

Eur J Pediatr. 2005 May;164(5):271-6. Epub 2005 Jan 14.

PMID:
15650834
12.

The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection.

Guaraldi G, Stentarelli C, Zona S, Santoro A, Beghetto B, Carli F, Orlando G, Franceschetto A, Casolo A, Mussini C.

HIV Med. 2014 Nov;15(10):587-94. doi: 10.1111/hiv.12159. Epub 2014 Apr 21.

13.

Lipodystrophy, insulin resistance, and adiponectin concentration in HIV-infected children and adolescents.

Viganò A, Zuccotti GV, Cerini C, Stucchi S, Puzzovio M, Giacomet V, Mora S.

Curr HIV Res. 2011 Jul;9(5):321-6.

PMID:
21827385
14.

Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.

Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Viganò A.

AIDS. 2001 Dec 7;15(18):2415-22.

PMID:
11740192
15.

Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy.

Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S.

AIDS. 2001 May 25;15(8):975-82.

PMID:
11399979
16.

Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.

Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J, Eckel R.

HIV Med. 2003 Jul;4(3):235-40.

17.

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.

Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):482-9.

PMID:
12679698
18.

Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls.

Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, Massip P, Perret B, Bernard J.

J Clin Densitom. 2007 Oct-Dec;10(4):376-80. Epub 2007 Sep 20.

PMID:
17888698
19.

Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy.

Freitas P, Carvalho D, Santos AC, Matos MJ, Madureira AJ, Marques R, Martinez E, Sarmento A, Medina JL.

J Endocrinol Invest. 2012 Dec;35(11):964-70. doi: 10.3275/8187. Epub 2011 Dec 16.

PMID:
22186163
20.

Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.

Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.

Antivir Ther. 2007;12(1):97-105.

PMID:
17503753

Supplemental Content

Support Center